MDM2 and neuroblastoma: We targeted these endpoints using the BET inhibitor OTX015 and the MDM2 inhibitor CGM097 and demonstrated a synergistic increase in cell death, activation of the p53 pathway, and a significant increase in time to event in vivo, further implicating these pathways in the biology and treatment of NB.